Search results

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 07 January 2021

A new version of this vaccine information for UK healthcare professionals includes (in Section 6.6) allowing for an additional dose to be taken if there is sufficient liquid left for a further full...

Read Summary

Type:

Medicines Current Awareness (Remove filter)

Type:

Guidance (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 30 December 2020

The JCVI has subsequently recommended that as many people on the priority list as possible should be offered a first vaccine dose as the initial priority (as opposed to prioritising completing the 2...

Read Summary

SPS comment

Type:

Medicines Current Awareness (Remove filter)

Type:

Guidance (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 08 January 2021

This is the third Covid-19 vaccine (the second mRNA vaccine) to have been given regulatory approval for supply by the MHRA. It is approved for use in people aged 18 years and requires two doses.

Read Summary

SPS comment

Type:

Medicines Current Awareness (Remove filter)

Type:

Guidance (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 08 January 2021

The REMAP-CAP platform trial has reported survival and time to recovery benefits for tocilizumab or sarilumab. Clinicians should consider prescribing IV tocilizumab (sarilumab an alternative if...

Read Summary

SPS comment

Type:

Medicines Current Awareness (Remove filter)

Type:

Guidance (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 January 2021

This guidance signposts patients, healthcare professionals and developers of new medicines to advice and resources on medicines in pregnancy and breastfeeding and is supported by Safer Medicines in...

Read Summary

SPS comment

Type:

Medicines Current Awareness (Remove filter)

Type:

Guidance (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 12 February 2021

Colchicine should NOT be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use. Although early...

Read Summary

SPS comment

Type:

Medicines Current Awareness (Remove filter)

Type:

Guidance (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 01 December 2020

Alert warns that if large volumes of pleural fluid are drained too quickly from chest drains, patients can rapidly deteriorate from the potentially life-threatening complication of re-expansion...

Read Summary

SPS comment

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 09 December 2020

MHRA has advised that any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer/BioNTech vaccine; and a second dose should not be given to anyone who has...

Read Summary

SPS comment

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 07 January 2021

Data from observational studies suggest use of SSRI/SNRI antidepressants during month before delivery may result in small increased risk of postpartum haemorrhage. Prescribers should consider this...

Read Summary

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 17 December 2020

Erythromycin should not be given to patients with a history of QT interval prolongation or ventricular cardiac arrhythmia. A potential drug interaction between rivaroxaban and erythromycin resulting...

Read Summary

SPS comment

Type:

Safety Alerts (Add filter)

Type:

Medicines Current Awareness (Remove filter)